Capital Fund Management S.A. Purchases 188,000 Shares of The Chemours Company $CC

Key Points

• Capital Fund Management S.A. increased its stake in The Chemours Company by 103.5% in Q1, acquiring an additional 188,000 shares to reach a total of 369,579 shares valued at approximately $5 million.
• Several large investors, including UMB Bank and Farther Finance Advisors, also significantly increased their holdings in Chemours during the last two quarters.
• The Chemours Company recently reported a better-than-expected earnings per share of $0.58 for the last quarter, surpassing analysts' expectations, along with a revenue increase of 5% year-over-year.

Capital Fund Management S.A. lifted its stake in The Chemours Company (NYSE:CC - Free Report) by 103.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 369,579 shares of the specialty chemicals company's stock after purchasing an additional 188,000 shares during the period. Capital Fund Management S.A. owned 0.25% of Chemours worth $5,000,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. UMB Bank n.a. lifted its position in shares of Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares during the period. Itau Unibanco Holding S.A. lifted its position in shares of Chemours by 39.3% in the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after purchasing an additional 1,003 shares during the period. Captrust Financial Advisors lifted its position in shares of Chemours by 9.7% in the 4th quarter. Captrust Financial Advisors now owns 13,130 shares of the specialty chemicals company's stock worth $222,000 after purchasing an additional 1,165 shares during the period. Brown Advisory Inc. lifted its position in shares of Chemours by 6.0% in the 1st quarter. Brown Advisory Inc. now owns 20,874 shares of the specialty chemicals company's stock worth $282,000 after purchasing an additional 1,174 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 1,444 shares during the period. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Stock Up 0.4%

NYSE:CC traded up $0.07 on Wednesday, reaching $15.26. 1,170,248 shares of the stock traded hands, compared to its average volume of 3,556,678. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.45 and a beta of 1.61. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The Chemours Company has a 12 month low of $9.13 and a 12 month high of $22.38. The company's fifty day simple moving average is $13.07 and its 200 day simple moving average is $12.87.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the business earned $0.38 EPS. Chemours's revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be issued a $0.0875 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.3%. Chemours's dividend payout ratio (DPR) is presently -12.50%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on CC shares. Morgan Stanley dropped their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Barclays decreased their price target on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 28th. UBS Group decreased their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada increased their price target on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research note on Thursday, July 3rd. Finally, Mizuho increased their price target on shares of Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $17.38.

Insider Buying and Selling

In other Chemours news, insider Damian Gumpel acquired 13,400 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were bought at an average price of $9.22 per share, with a total value of $123,548.00. Following the completion of the acquisition, the insider owned 123,879 shares in the company, valued at $1,142,164.38. This represents a 12.13% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Denise Dignam acquired 4,068 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at $2,310,044.76. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 25,290 shares of company stock worth $250,437. 0.34% of the stock is currently owned by insiders.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.